Risk of cancers during interrupted antiretroviral therapy in the SMART study.
about
Lung cancer in HIV-infected patients in the combination antiretroviral treatment eraDeveloping clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in KenyaHuman papillomavirus-related diseases in HIV-infected individualsLong-term nitrite inhalant exposure and cancer risk in MSM.Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkersHIV infection and the risk of cancers with and without a known infectious cause.Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.HIV and cancer in GermanyAn internationally generalizable risk index for mortality after one year of antiretroviral therapy.Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisInferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapyCD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settingsIncreased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.Cancer prevention in HIV-infected populations.CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infectionKaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management.Evolving spectrum and incidence of non-AIDS-defining malignancies.Cutaneous malignancies among HIV-infected persons.Motivation and patch treatment for HIV+ smokers: a randomized controlled trial.Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this riskCancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998-2009.Considerations for Endpoint Selection When Designing HIV Clinical Trials.Incidence and risk of lung cancer in HIV-infected patients.A cure for HIV: is it in sight?Towards an HIV-1 cure: measuring the latent reservoir.Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.
P2860
Q26769769-25831715-D4EE-4BCA-886F-C88D51207320Q28539066-6C10F474-1AE2-43BD-BE47-A4ACCAEC8BD2Q33395603-4FBBF53D-F196-4AC8-99C0-C78903CA392CQ33631041-88AF07AC-C61E-4B66-8C50-1CA3049DB97AQ33651611-53EBF577-25C7-45B1-9C0B-C488C1B1F2C7Q33696149-4F7473AA-10DF-4D89-B398-8398B06CFE3AQ33713347-AF7AD516-DEB1-447F-9381-C977A42EC7E4Q33827510-EE22F7DB-594D-4B79-ADE2-DBA8662B1F53Q34011661-03C8CB62-20E6-4226-B0EC-1C69EB445FE0Q34050143-907A4736-3B21-4E4C-9715-FD2E7704A7B5Q34660212-767D1C29-E95E-4116-B508-E7EE1982CC98Q34813110-8D7E9DEB-B853-421B-B9E7-B728383845D4Q35030752-8643B079-5D9B-4353-9B5C-7EA15EDF31B4Q35063571-83B307B5-E2A9-469B-9D80-A0523F3B8D04Q35129228-B83FDCBF-2E80-4645-97AC-1A62366CEA60Q35250302-F58A0A26-03AC-45ED-8F73-54B3C5DE0A7EQ35562938-E8228E3D-7748-42AA-8485-CBD7F0983E66Q35850380-6EF80E4E-6C29-4CBE-AF80-67D6CA7AFB86Q35958548-80745CC9-BA81-49BB-B819-48D1352EA8C2Q36036666-BB122BE7-7392-4376-94EC-26436835792EQ36132370-4FD9B4AD-1DD9-44E2-8695-DE01E04FF688Q36162341-C4EC45FB-D1CD-478B-912A-45035D093218Q36246252-120C704B-77E3-4B87-B5C0-595D12CF7F56Q36680086-C9401B7E-F26D-4BDD-B020-F95E452414D8Q36745251-4224C622-B838-4B8C-A6AE-3AD7FAB7A14CQ36859148-61212820-5E9C-41A6-98FD-DC75BA9BA9B6Q36875697-E8273BBD-9231-4FB0-AA9C-4504B70924E2Q37178883-61835E0D-8086-4984-B91C-E01CAEE6A17BQ37233212-B8CA9540-2E17-44B6-97C6-5B3540A8A857Q37351970-8E732B65-4785-4044-8183-B03224F14D6FQ37353390-7D62EB49-0EC3-4E92-9673-7955DB97B3DFQ37387284-36BDFE8E-B8D1-4607-A0D3-1E6BC790D8D4Q37389719-010B593E-D230-4588-9BBC-5A739B24C9E0Q37712406-4AE8CEB1-D915-44CA-A662-3A141917C63EQ37717137-BF4EB646-49B1-4C10-A541-74748749A6EDQ37967498-6CC30A55-FDFF-403C-9430-D55FEBBFF32EQ38124683-6248A622-F572-4325-B857-9DD2F17530BDQ38205472-739DA1DD-0644-459D-BA93-CBA1B301FBE6Q38369541-31096D49-343C-4348-AC1A-8000097787F4Q38853095-267361EB-C679-41A0-B12D-DC2BE2FA027D
P2860
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@ast
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@en
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@nl
type
label
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@ast
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@en
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@nl
prefLabel
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@ast
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@en
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@nl
P2093
P1433
P1476
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
@en
P2093
Angelos Hatzakis
Daniela Gey
Donald I Abrams
Jacqueline Neuhaus
James D Neaton
Jose Hidalgo
Keith Henry
Leonardo Lourtau
Michael J Silverberg
P304
P356
10.1097/QAD.0B013E3282ED6338
P407
P577
2007-09-01T00:00:00Z